Andela et al. [128] published the earliest report we could find of RUNX2 immunoreactivity in osteosarcomas; the researchers tested 11 pathology specimens of the cancer and found RUNX2 immunopositivity in all of them. Here, RUNX2 is linked to osteosarcoma.